Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Modeling the clinical phenotype of BTK inhibition in the mature murine immune system.

Benson MJ, Rodriguez V, von Schack D, Keegan S, Cook TA, Edmonds J, Benoit S, Seth N, Du S, Messing D, Nickerson-Nutter CL, Dunussi-Joannopoulos K, Rankin AL, Ruzek M, Schnute ME, Douhan J 3rd.

J Immunol. 2014 Jul 1;193(1):185-97. doi: 10.4049/jimmunol.1302570. Epub 2014 Jun 4.

2.

Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.

Rankin AL, Seth N, Keegan S, Andreyeva T, Cook TA, Edmonds J, Mathialagan N, Benson MJ, Syed J, Zhan Y, Benoit SE, Miyashiro JS, Wood N, Mohan S, Peeva E, Ramaiah SK, Messing D, Homer BL, Dunussi-Joannopoulos K, Nickerson-Nutter CL, Schnute ME, Douhan J 3rd.

J Immunol. 2013 Nov 1;191(9):4540-50. doi: 10.4049/jimmunol.1301553. Epub 2013 Sep 25.

3.

B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the interleukin-17 response.

Kozakiewicz L, Chen Y, Xu J, Wang Y, Dunussi-Joannopoulos K, Ou Q, Flynn JL, Porcelli SA, Jacobs WR Jr, Chan J.

PLoS Pathog. 2013;9(7):e1003472. doi: 10.1371/journal.ppat.1003472. Epub 2013 Jul 11.

4.

Variants within STAT genes reveal association with anticitrullinated protein antibody-negative rheumatoid arthritis in 2 European populations.

Seddighzadeh M, Gonzalez A, Ding B, Ferreiro-Iglesias A, Gomez-Reino JJ; Rheumatoid Arthritis Network and Coordinated Project, Klareskog L, Alfredsson L, Dunussi-Joannopoulos K, Clark JD, Padyukov L.

J Rheumatol. 2012 Aug;39(8):1509-16. doi: 10.3899/jrheum.111284. Epub 2012 Jul 1.

PMID:
22753649
5.

Enhanced GITR/GITRL interactions augment IL-27 expression and induce IL-10-producing Tr-1 like cells.

Carrier Y, Whitters MJ, Miyashiro JS, LaBranche TP, Ramon HE, Benoit SE, Ryan MS, Keegan SP, Guay H, Douhan J, Collins M, Dunussi-Joannopoulos K, Medley QG.

Eur J Immunol. 2012 Jun;42(6):1393-404. doi: 10.1002/eji.201142162.

6.

IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice.

Rankin AL, Guay H, Herber D, Bertino SA, Duzanski TA, Carrier Y, Keegan S, Senices M, Stedman N, Ryan M, Bloom L, Medley Q, Collins M, Nickerson-Nutter C, Craft J, Young D, Dunussi-Joannopoulos K.

J Immunol. 2012 Feb 15;188(4):1656-67. doi: 10.4049/jimmunol.1003871. Epub 2012 Jan 9.

7.

IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice.

Van Belle AB, de Heusch M, Lemaire MM, Hendrickx E, Warnier G, Dunussi-Joannopoulos K, Fouser LA, Renauld JC, Dumoutier L.

J Immunol. 2012 Jan 1;188(1):462-9. doi: 10.4049/jimmunol.1102224. Epub 2011 Nov 30.

8.

Inotuzumab ozogamicin murine analog-mediated B-cell depletion reduces anti-islet allo- and autoimmune responses.

Carvello M, Petrelli A, Vergani A, Lee KM, Tezza S, Chin M, Orsenigo E, Staudacher C, Secchi A, Dunussi-Joannopoulos K, Sayegh MH, Markmann JF, Fiorina P.

Diabetes. 2012 Jan;61(1):155-65. doi: 10.2337/db11-0684. Epub 2011 Nov 10.

9.

Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.

Kim KH, Maderna A, Schnute ME, Hegen M, Mohan S, Miyashiro J, Lin L, Li E, Keegan S, Lussier J, Wrocklage C, Nickerson-Nutter CL, Wittwer AJ, Soutter H, Caspers N, Han S, Kurumbail R, Dunussi-Joannopoulos K, Douhan J 3rd, Wissner A.

Bioorg Med Chem Lett. 2011 Nov 1;21(21):6258-63. doi: 10.1016/j.bmcl.2011.09.008. Epub 2011 Sep 10.

PMID:
21958547
10.

B cell depletion reduces the number of autoreactive T helper cells and prevents glucose-6-phosphate isomerase-induced arthritis.

Frey O, Bruns L, Morawietz L, Dunussi-Joannopoulos K, Kamradt T.

PLoS One. 2011;6(9):e24718. doi: 10.1371/journal.pone.0024718. Epub 2011 Sep 8.

11.

Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis.

Carrier Y, Ma HL, Ramon HE, Napierata L, Small C, O'Toole M, Young DA, Fouser LA, Nickerson-Nutter C, Collins M, Dunussi-Joannopoulos K, Medley QG.

J Invest Dermatol. 2011 Dec;131(12):2428-37. doi: 10.1038/jid.2011.234. Epub 2011 Sep 1.

12.

GM-CSF in the lung protects against lethal influenza infection.

Huang FF, Barnes PF, Feng Y, Donis R, Chroneos ZC, Idell S, Allen T, Perez DR, Whitsett JA, Dunussi-Joannopoulos K, Shams H.

Am J Respir Crit Care Med. 2011 Jul 15;184(2):259-68. doi: 10.1164/rccm.201012-2036OC. Epub 2011 Apr 7.

PMID:
21474645
13.

Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys.

Nickerson-Nutter C, Tchistiakova L, Seth NP, Kasaian M, Sibley B, Olland S, Zollner R, Brady WA, Mohler KM, Baum P, Wahl A, Herber D, Vugmeyster Y, Wensel D, Wolfman NM, Gill D, Collins M, Dunussi-Joannopoulos K.

Rheumatology (Oxford). 2011 Jun;50(6):1033-44. doi: 10.1093/rheumatology/keq423. Epub 2011 Jan 21.

14.

IL-22 induces an acute-phase response.

Liang SC, Nickerson-Nutter C, Pittman DD, Carrier Y, Goodwin DG, Shields KM, Lambert AJ, Schelling SH, Medley QG, Ma HL, Collins M, Dunussi-Joannopoulos K, Fouser LA.

J Immunol. 2010 Nov 1;185(9):5531-8. doi: 10.4049/jimmunol.0904091. Epub 2010 Sep 24.

15.

B1 cells promote pancreas infiltration by autoreactive T cells.

Ryan GA, Wang CJ, Chamberlain JL, Attridge K, Schmidt EM, Kenefeck R, Clough LE, Dunussi-Joannopoulos K, Toellner KM, Walker LS.

J Immunol. 2010 Sep 1;185(5):2800-7. doi: 10.4049/jimmunol.1000856. Epub 2010 Jul 30.

16.

Th17 cytokines and their emerging roles in inflammation and autoimmunity.

Fouser LA, Wright JF, Dunussi-Joannopoulos K, Collins M.

Immunol Rev. 2008 Dec;226:87-102. doi: 10.1111/j.1600-065X.2008.00712.x. Review.

PMID:
19161418
17.

Targeting CD22 reprograms B-cells and reverses autoimmune diabetes.

Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, Law K, Wu E, Tian Z, Abdi R, Guleria I, Rodig S, Dunussi-Joannopoulos K, Bluestone J, Sayegh MH.

Diabetes. 2008 Nov;57(11):3013-24. doi: 10.2337/db08-0420. Epub 2008 Aug 8.

18.

The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex.

Wright JF, Bennett F, Li B, Brooks J, Luxenberg DP, Whitters MJ, Tomkinson KN, Fitz LJ, Wolfman NM, Collins M, Dunussi-Joannopoulos K, Chatterjee-Kishore M, Carreno BM.

J Immunol. 2008 Aug 15;181(4):2799-805.

19.

IL-22R, IL-10R2, and IL-22BP binding sites are topologically juxtaposed on adjacent and overlapping surfaces of IL-22.

Wu PW, Li J, Kodangattil SR, Luxenberg DP, Bennett F, Martino M, Collins M, Dunussi-Joannopoulos K, Gill DS, Wolfman NM, Fouser LA.

J Mol Biol. 2008 Oct 24;382(5):1168-83. doi: 10.1016/j.jmb.2008.07.046. Epub 2008 Jul 25.

PMID:
18675824
20.

IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation.

Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, Senices M, Gill D, Dunussi-Joannopoulos K, Collins M, Nickerson-Nutter C, Fouser LA, Young DA.

J Clin Invest. 2008 Feb;118(2):597-607. doi: 10.1172/JCI33263.

21.

A FLIPR-based assay to assess potency and selectivity of inhibitors of the TEC family kinases Btk and Itk.

Douhan J 3rd, Miyashiro JS, Zhou X, Cole DC, Wu PW, Collins M, Dunussi-Joannopoulos K.

Assay Drug Dev Technol. 2007 Dec;5(6):751-8. doi: 10.1089/adt.2007.9982.

PMID:
18181691
22.

An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment.

Liang SC, Long AJ, Bennett F, Whitters MJ, Karim R, Collins M, Goldman SJ, Dunussi-Joannopoulos K, Williams CM, Wright JF, Fouser LA.

J Immunol. 2007 Dec 1;179(11):7791-9.

23.

Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells.

Wright JF, Guo Y, Quazi A, Luxenberg DP, Bennett F, Ross JF, Qiu Y, Whitters MJ, Tomkinson KN, Dunussi-Joannopoulos K, Carreno BM, Collins M, Wolfman NM.

J Biol Chem. 2007 May 4;282(18):13447-55. Epub 2007 Mar 13.

24.

IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression.

Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K.

J Immunol. 2007 Mar 15;178(6):3822-30.

25.

Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides.

Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA.

J Exp Med. 2006 Oct 2;203(10):2271-9. Epub 2006 Sep 18.

26.

B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors.

Hiraoka S, Takeuchi N, Bian Y, Nakahara H, Kogo M, Dunussi-Joannopoulos K, Wolf S, Ono S, Fujiwara H.

Int Immunol. 2005 Aug;17(8):1071-9. Epub 2005 Jul 18.

PMID:
16027141
27.

B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model.

Dunussi-Joannopoulos K, Hancock GE, Kunz A, Hegen M, Zhou XX, Sheppard BJ, Lamothe J, Li E, Ma HL, Hamann PR, Damle NK, Collins M.

Blood. 2005 Oct 1;106(7):2235-43. Epub 2005 Jun 9.

PMID:
15947095
28.

The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.

Bian Y, Hiraoka S, Tomura M, Zhou XY, Yashiro-Ohtani Y, Mori Y, Shimizu J, Ono S, Dunussi-Joannopoulos K, Wolf S, Fujiwara H.

Int Immunol. 2005 Jan;17(1):73-83. Epub 2004 Nov 29.

PMID:
15569772
29.

Tumor cells secreting IL-13 but not IL-13Ralpha2 fusion protein have reduced tumorigenicity in vivo.

Ma HL, Whitters MJ, Jacobson BA, Donaldson DD, Collins M, Dunussi-Joannopoulos K.

Int Immunol. 2004 Jul;16(7):1009-17. Epub 2004 Jun 7.

PMID:
15184346
30.

Induction of tumor regression by administration of B7-Ig fusion proteins: mediation by type 2 CD8+ T cells and dependence on IL-4 production.

Yamaguchi N, Hiraoka S, Mukai T, Takeuchi N, Zhou XY, Ono S, Kogo M, Dunussi-Joannopoulos K, Ling V, Wolf S, Fujiwara H.

J Immunol. 2004 Feb 1;172(3):1347-54.

31.
32.

IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma.

Ma HL, Whitters MJ, Konz RF, Senices M, Young DA, Grusby MJ, Collins M, Dunussi-Joannopoulos K.

J Immunol. 2003 Jul 15;171(2):608-15.

33.
34.
35.

Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with Adriamycin and Cytoxan chemotherapy.

Zhou H, Sequeira M, Goad ME, Erickson J, Wong A, Clark E, Dunussi-Joannopoulos K, Li RC, Friedrich S, Hayes LL, Wolf SF.

Clin Immunol. 2001 Dec;101(3):303-14.

PMID:
11726223
36.
37.

Interleukin-12 gene therapy vaccines: directing the immune system against minimal residual leukemia.

Dunussi-Joannopoulos K, Leonard JP.

Leuk Lymphoma. 2001 May;41(5-6):483-92. Review.

PMID:
11378566
38.
39.

Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia.

Dahl GV, Lacayo NJ, Brophy N, Dunussi-Joannopoulos K, Weinstein HJ, Chang M, Sikic BI, Arceci RJ.

J Clin Oncol. 2000 May;18(9):1867-75.

PMID:
10784627
40.

Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity.

Dunussi-Joannopoulos K, Runyon K, Erickson J, Schaub RG, Hawley RG, Leonard JP.

Blood. 1999 Dec 15;94(12):4263-73.

PMID:
10590071
41.

Autocrine regulation of IL-12 receptor expression is independent of secondary IFN-gamma secretion and not restricted to T and NK cells.

Thibodeaux DK, Hunter SE, Waldburger KE, Bliss JL, Trepicchio WL, Sypek JP, Dunussi-Joannopoulos K, Goldman SJ, Leonard JP.

J Immunol. 1999 Nov 15;163(10):5257-64.

43.

Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model.

Dunussi-Joannopoulos K, Weinstein HJ, Arceci RJ, Croop JM.

J Pediatr Hematol Oncol. 1997 Nov-Dec;19(6):536-40. Review.

PMID:
9407942
44.

Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein.

Bosch I, Dunussi-Joannopoulos K, Wu RL, Furlong ST, Croop J.

Biochemistry. 1997 May 13;36(19):5685-94.

PMID:
9153408
45.

CD8+ T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment.

Dunussi-Joannopoulos K, Krenger W, Weinstein HJ, Ferrara JL, Croop JM.

Blood. 1997 Apr 15;89(8):2915-24.

PMID:
9108412
46.

Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML.

Dunussi-Joannopoulos K, Weinstein HJ, Nickerson PW, Strom TB, Burakoff SJ, Croop JM, Arceci RJ.

Blood. 1996 Apr 1;87(7):2938-46.

PMID:
8639914

Supplemental Content

Loading ...
Support Center